Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Oncotelic Therapeutics, Inc. (MATN)
|
Add to portfolio |
|
|
|
| Price: |
$0.27
| | Metrics |
| OS: |
398.2
|
M
| |
|
|
| Market cap: |
$106
|
M
| |
|
|
|
Net cash:
|
$107.8
|
k
| |
$0.00
|
per share
|
|
EV:
|
$105
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($5.1)
|
M
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 0.0 | 1.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Revenue growth | -100.0% | | | | | | | -100.0% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 1.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross margin | | 100.0% | | | | | | |
| Research and development | 3.7 | 4.3 | 1.4 | 0.6 | 10.5 | 8.8 | 9.1 | 7.4 |
| General and administrative | 5.5 | 5.0 | 2.9 | 0.1 | 3.4 | 5.0 | 4.6 | 5.2 |
| EBITA | -9.1 | -7.3 | -4.3 | -0.7 | -13.8 | -13.8 | -13.7 | -12.6 |
| EBITA margin | | -416.9% | | | | | | |
| Amortization of intangibles | 0.1 | 0.3 | 0.1 | 0.0 | | | | 0.1 |
| EBIT | -9.1 | -7.6 | -4.3 | -0.7 | -13.8 | -13.8 | -13.7 | -12.7 |
| EBIT margin | | -435.7% | | | | | | |
| Pre-tax income | -10.5 | -10.0 | -6.6 | -0.7 | -13.8 | -13.7 | -13.7 | -12.6 |
| Income taxes | -1.1 | -0.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 10.7% | 4.7% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -9.4 | -9.5 | -6.6 | -0.7 | -13.8 | -13.7 | -13.7 | -12.6 |
| Net margin | | -545.9% | | | | | | |
| |
| Diluted EPS | ($0.03) | ($0.11) | ($0.11) | ($0.12) | ($0.52) | ($0.51) | ($0.54) | ($0.75) |
| Shares outstanding (diluted) | 303.1 | 88.1 | 60.0 | 6.1 | 26.5 | 26.5 | 25.2 | 17.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|